UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) by 28.2% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,691 shares of the company's stock after buying an additional 12,462 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.08% of Kiniksa Pharmaceuticals worth $1,121,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Lazard Asset Management LLC bought a new stake in Kiniksa Pharmaceuticals in the 4th quarter valued at $61,000. KLP Kapitalforvaltning AS acquired a new stake in shares of Kiniksa Pharmaceuticals during the fourth quarter worth $158,000. Bellevue Group AG bought a new position in shares of Kiniksa Pharmaceuticals in the fourth quarter worth $160,000. Tower Research Capital LLC TRC increased its position in shares of Kiniksa Pharmaceuticals by 117.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,483 shares of the company's stock worth $168,000 after purchasing an additional 4,575 shares during the period. Finally, Teacher Retirement System of Texas lifted its holdings in shares of Kiniksa Pharmaceuticals by 7.1% during the fourth quarter. Teacher Retirement System of Texas now owns 10,862 shares of the company's stock worth $215,000 after purchasing an additional 719 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

Insider Buying and Selling

In related news, insider Ross Moat sold 64,035 shares of the business's stock in a transaction dated Tuesday, April 29th. The shares were sold at an average price of $25.21, for a total transaction of $1,614,322.35. Following the sale, the insider now owns 9,415 shares of the company's stock, valued at approximately $237,352.15. The trade was a 87.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Eben Tessari sold 45,042 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total transaction of $1,374,231.42. Following the transaction, the chief operating officer now owns 72,363 shares of the company's stock, valued at approximately $2,207,795.13. The trade was a 38.36% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 443,906 shares of company stock valued at $12,081,708. Corporate insiders own 54.57% of the company's stock.

Kiniksa Pharmaceuticals Stock Up 2.1%

Kiniksa Pharmaceuticals stock traded up $0.57 during mid-day trading on Friday, reaching $28.30. 907,293 shares of the company's stock were exchanged, compared to its average volume of 515,189. Kiniksa Pharmaceuticals, Ltd. has a twelve month low of $17.38 and a twelve month high of $30.69. The company has a fifty day moving average of $25.12 and a 200-day moving average of $22.17. The company has a market cap of $2.07 billion, a P/E ratio of -202.13 and a beta of 0.06.

Kiniksa Pharmaceuticals (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals had a negative net margin of 2.36% and a negative return on equity of 7.31%. Kiniksa Pharmaceuticals's revenue for the quarter was up 72.5% on a year-over-year basis. During the same period last year, the firm posted ($0.25) EPS. Equities research analysts expect that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on KNSA shares. Citigroup assumed coverage on shares of Kiniksa Pharmaceuticals in a research report on Thursday, March 13th. They set a "buy" rating and a $40.00 target price for the company. Wall Street Zen cut shares of Kiniksa Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, June 6th. Wedbush reaffirmed an "outperform" rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Wednesday, April 16th. Finally, Jefferies Financial Group upped their price target on shares of Kiniksa Pharmaceuticals from $40.00 to $45.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $38.80.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.